BMO Capital Markets Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective reduced by equities researchers at BMO Capital Markets from $800.00 to $600.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 22.99% […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective reduced by equities researchers at BMO Capital Markets from $800.00 to $600.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 22.99% […]
